Improvement of Women's Health After Allogeneic Stem Cell Transplantation
ConditionGVHD, Chronic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorCiusss de L'Est de l'Île de Montréal
About this trial
The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women.
Eligibility criteria
Qualifiers
All women aged 18 and over who will receive a first allogeneic HSCT (bone marrow, peripheral blood stem cells from a related, unrelated (including cord blood) or haploidentical donor) at the CIUSSS-EMTL. Recruitment will begin when the project receives ethical approval. Recruitment period will be of 2 to 3 years.
Disqualifiers
Those who receive a second HSCT allograft.
Those who receive an autologous transplant.
Inability to give informed consent.
Unable to communicate in French or English.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Ciusss de L'Est de l'Île de Montréal
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborator
Source ClinicalTrials.gov